An unusual case of HIV virologic failure during treatment with boosted atazanavir. - Suppr | 超能文献

An unusual case of HIV virologic failure during treatment with boosted atazanavir.

作者信息

Duncan Alison, Mills John

出版信息

AIDS. 2013 May 15;27(8):1361-2. doi: 10.1097/QAD.0b013e32835fac84.

DOI:10.1097/QAD.0b013e32835fac84

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

An unusual case of HIV virologic failure during treatment with boosted atazanavir.

AIDS. 2013 May 15;27(8):1361-2. doi: 10.1097/QAD.0b013e32835fac84.

2

[New data on atazanavir/r]].[关于阿扎那韦/利托那韦的新数据]。

MMW Fortschr Med. 2005 Apr 25;147 Spec No 1:81-3.

3

Atazanavir: clinical use.

Hopkins HIV Rep. 2003 Jul;15(4):3-4.

4

Atazanavir: a novel inhibitor of HIV-protease in haemodialysis.

Nephrol Dial Transplant. 2005 Apr;20(4):852-3. doi: 10.1093/ndt/gfh684.

5

Efficacy and safety of atazanavir-based highly active antiretroviral therapy in patients with virologic suppression switched from a stable, boosted or unboosted protease inhibitor treatment regimen: the SWAN Study (AI424-097) 48-week results.基于阿扎那韦的高效抗逆转录病毒疗法在从稳定的、加用或未加用增效剂的蛋白酶抑制剂治疗方案转换过来且病毒学得到抑制的患者中的疗效和安全性：SWAN研究（AI424 - 097）48周结果

Clin Infect Dis. 2007 Jun 1;44(11):1484-92. doi: 10.1086/517497. Epub 2007 Apr 25.

6

Limited sampling strategies for the estimation of atazanavir daily exposure in HIV-infected patients.用于估算 HIV 感染患者阿扎那韦日暴露量的有限采样策略。

Fundam Clin Pharmacol. 2013 Apr;27(2):216-22. doi: 10.1111/j.1472-8206.2011.01005.x. Epub 2011 Nov 2.

7

Drug profile: atazanavir (Reyataz, ATV).

Hopkins HIV Rep. 2003 Jul;15(4):4-5.

8

Virological failure and subsequent resistance profiles in individuals exposed to atazanavir.接受阿扎那韦治疗的个体的病毒学失败及后续耐药情况。

AIDS. 2007 Aug 20;21(13):1826-8. doi: 10.1097/QAD.0b013e3282742000.

9

[Evidence-based therapeutic drug monitoring of atazanavir].[阿扎那韦的循证治疗药物监测]

Therapie. 2011 May-Jun;66(3):213-9. doi: 10.2515/therapie/2011032. Epub 2011 Aug 9.

10

Atazanavir for treatment of HIV infection in clinical routine: efficacy, pharmacokinetics and safety.临床常规使用阿扎那韦治疗HIV感染：疗效、药代动力学及安全性

Eur J Med Res. 2005 Jan 28;10(1):7-10.

引用本文的文献

1

Mechanism-Driven and Clinically Focused Development of Botanical Foods as Multitarget Anticancer Medicine: Collective Perspectives and Insights from Preclinical Studies, IND Applications and Early-Phase Clinical Trials.作为多靶点抗癌药物的植物性食品的机制驱动与临床聚焦开发：来自临床前研究、新药临床试验申请及早期临床试验的综合观点与见解

Cancers (Basel). 2023 Jan 23;15(3):701. doi: 10.3390/cancers15030701.

2

Potential Influence of Centrally Acting Herbal Drugs on Transporters at the Blood-Cerebrospinal Fluid Barrier and Blood-Brain Barrier.中枢作用草药对血脑脊液屏障和血脑屏障转运体的潜在影响。

Eur J Drug Metab Pharmacokinet. 2018 Dec;43(6):619-635. doi: 10.1007/s13318-018-0486-6.

3

Sub-therapeutic darunavir concentration and garlic consumption; a «Mediterranean» drug-food interaction, about 2 cases.低于治疗浓度的达芦那韦与大蒜摄入：一种“地中海式”药物-食物相互作用，约2例。

Eur J Clin Pharmacol. 2017 Oct;73(10):1331-1333. doi: 10.1007/s00228-017-2300-9. Epub 2017 Jul 11.